OOIR: Observatory of International Research

Papers

(The TQCC of Cellular & Molecular Immunology is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications	1310
Necroptosis, pyroptosis and apoptosis: an intricate game of cell death	861
NLRP3 inflammasome activation and cell death	560
Tumor-infiltrating lymphocytes in the immunotherapy era	448
Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities	337
An update on the regulatory mechanisms of NLRP3 inflammasome activation	336
SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70	286
A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity	263
Macrophages and the maintenance of homeostasis	220
Neutrophils in chronic inflammatory diseases	216
The blood–brain barrier in systemic infection and inflammation	203
Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases	202
Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients	198
Gut microbiome, liver immunology, and liver diseases	196
Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors	194
Cancer immunotherapy with γδ T cells: many paths ahead of us	191
Dendritic cell migration in inflammation and immunity	186
Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids	178
Unique immunological profile in patients with COVID-19	176
Increased immune escape of the new SARS-CoV-2 variant of concern Omicron	173
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells	168
New insights into the evasion of host innate immunity by Mycobacterium tuberculosis	161
Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients	159
Metabolism of tissue macrophages in homeostasis and pathology	151
SARS-CoV-2 membrane glycoprotein M antagonizes the MAVS-mediated innate antiviral response	141

Manganese salts function as potent adjuvants	136
SARS-CoV-2-specific T cells in infection and vaccination	133
Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer	126
Activation or exhaustion of CD8+ T cells in patients with COVID-19	120
The cutting-edge progress of immune-checkpoint blockade in lung cancer	115
SARS-CoV-2 ORF10 suppresses the antiviral innate immune response by degrading MAVS through mitophagy	115
Tumor-associated myeloid cells: diversity and therapeutic targeting	112
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors	111
Immunological mechanisms and therapeutic targets of fatty liver diseases	111
Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients	110
Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon response	106
Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases	105
Dendritic cells in cancer immunology	104
Phages and their potential to modulate the microbiome and immunity	98
SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation	97
Human immunology and immunotherapy: main achievements and challenges	96
Neutralizing antibodies for the prevention and treatment of COVID-19	93
New insights into the cell- and tissue-specificity of glucocorticoid actions	87
Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment	86
Neutrophils in liver diseases: pathogenesis and therapeutic targets	85
Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies	85
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods	84
Ligand recognition by the γδ TCR and discrimination between homeostasis and stress conditions	81
Pyroptotic macrophages stimulate the SARS-CoV-2-associated cytokine storm	79
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection	79
Immunopathobiology and therapeutic targets related to cytokines in liver diseases	78
T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant	78
USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy	77
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor	74
Expansion of atypical memory B cells is a prominent feature of COVID-19	73
Impact of intracellular innate immune receptors on immunometabolism	72
Single-cell profiling reveals the trajectories of natural killer cell differentiation in bone marrow and a stress signature induced by acute myeloid leukemia	72
Autoimmmune hepatitis	72
“Autoinflammatory psoriasis”—genetics and biology of pustular psoriasis	71
A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract	69
Microglia as hackers of the matrix: sculpting synapses and the extracellular space	69
Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice	69
T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals	67
Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren’s syndrome by modulating the function of myeloid-derived suppressor cells	65
The aryl hydrocarbon receptor and the gut–brain axis	64
Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis	64
IFNγ signaling integrity in colorectal cancer immunity and immunotherapy	62
HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy	62
Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion	61
The roles of microglia in viral encephalitis: from sensome to therapeutic targeting	61
The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy	60
The soluble glycoprotein NMB (GPNMB) produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33	59
Protein N-myristoylation: functions and mechanisms in control of innate immunity	57
Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy	55
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation	55

Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19	54
Protein synthesis, degradation, and energy metabolism in T cell immunity	53
OTUD5 promotes innate antiviral and antitumor immunity through deubiquitinating and stabilizing STING	53
Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice	52
Diet, lipids, and antitumor immunity	51
Clinical development of CAR T cell therapy in China: 2020 update	50
Biology and pathology of the uterine microenvironment and its natural killer cells	50
Innate lymphocytes: pathogenesis and therapeutic targets of liver diseases and cancer	48
A novel CD4+ CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves’ orbitopathy	47